Why are investors suing Erasca, Inc. (NASDAQ: ERAS)?

The lawsuit alleges Erasca and certain executives made false or misleading statements about ERAS-0015, including claims tied to preclinical data and comparisons with a competitor’s research. Plaintiffs contend investors were not fully informed of risks that could affect the drug candidate and the company’s prospects.

What is the Erasca ERAS-0015 securities class action about?

The case centers on allegations that Erasca misrepresented or omitted important facts about ERAS-0015’s preclinical development. Investors claim the company failed to disclose issues related to data comparisons and intellectual property risks, potentially violating federal securities laws.

Did Erasca fail to disclose patent or trade secret risks related to ERAS-0015?

According to the complaint, Erasca allegedly did not adequately disclose that its use of certain comparative preclinical data could expose the company to patent and trade secret concerns involving Revolution Medicines. These allegations have not been proven and remain subject to litigation.

Who can participate in the Erasca investor lawsuit?

Investors who purchased or otherwise acquired Erasca securities during the period covered by the lawsuit and suffered losses may be eligible to participate. Eligibility depends on the specific facts, purchase dates, and losses involved in the case.

What is the August 10, 2026 deadline in the Erasca securities lawsuit?

August 10, 2026 is the deadline for eligible investors to ask the court to appoint them as lead plaintiff in the proposed federal securities class action. Serving as lead plaintiff is optional and is not required to potentially share in any future recovery.

Erasca, Inc. - Faruqi & Faruqi LLP

Erasca, Inc.

Join Action

Case Details

Ticker ERAS

Class Period 01/14/2025 - 04/26/2026

Lead Plaintiff Deadline 08/10/2026

Days Left to Seek Plaintiff

If you are an Erasca investor who suffered a loss and would like to learn more, you can provide your information below:

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Erasca To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Erasca between January 14, 2025 and April 26, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Erasca, Inc (“Erasca” or the “Company”) (NASDAQ: ERAS) and reminds investors of the August 10, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) ERAS-0015’s preclinical data was based on improper comparisons to Revolution Medicines, Inc. (“RevMed”) and placed Erasca at risk of violating patent and trade secret protections; and (2) based on the foregoing, Defendants lacked a reasonable basis for their positive statements related to ERAS-0015.

Lead Plaintiff Deadline: August 10, 2026

Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310)
Or submit your information below to learn about your rights.

Join Action

Erasca, Inc.

Monetary Losses ($) *

Website URL

First Name *

Last Name *

Telephone *

Email *

Street Address

City

State

Zip Code

Purchases

1	Purchases Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date
1	Purchases Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date

Add Row

Sales

1	Sales Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date
1	Sales Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date

Add Row

Upload your trades here:

Accepted file types: xls, xlsx, doc, docx, pdf, jpg, jpeg, png, Max. file size: 50 MB, Max. files: 5.
You may redact account numbers from your uploaded documents.

File name:

File size:

Select File

Does not establish an attorney-client relationship *

By clicking this box, I acknowledge that this form is not intended to and does not establish an attorney-client relationship between myself and Faruqi & Faruqi LLP, and that the submission or receipt of information via this form, e-mail or telephone does not create an attorney-client relationship.

Case

Users to notify